Are you Dr. Larkins?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 38 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
8901 Wisconsin Ave
Wrnmmc, Dept Of Hem-Onc, America Bldg, 3rd Floor
Bethesda, MD 20889Phone+1 301-319-2131
Summary
- Dr. Erin Larkins, MD is an oncologist in Bethesda, Maryland. She is currently licensed to practice medicine in Virginia. She is affiliated with Walter Reed National Military Medical Center and is an Assistant Professor at Uniformed Services Hebert SOM.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Uniformed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 2000
Certifications & Licensure
VA State Medical License 2001 - 2026- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Most Common Symptomatic Adverse Reactions of Cancer Treatments From US Drug Labels (2015-2021) to Inform Selection of Patient-Reported Outcomes.Erica G Horodniceanu, Tejaswi Datla, Meena N Murugappan, Bindu Kanapuru, Laleh Amiri-Kordestani
Value in Health. 2024-10-09 - 3 citationsImpact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials.Jonathon Vallejo, Harpreet Singh, Erin Larkins, Nicole Drezner, Biagio Ricciuti
The Oncologist. 2024-05-03 - 5 citationsCorrelations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled anal...Bernardo Haddock Lobo Goulart, Sirisha L Mushti, Somak Chatterjee, Erin Larkins, Pallavi S Mishra-Kalyani
The Lancet. Oncology. 2024-04-01
Press Mentions
Dr. David Gerber, University of Texas Southwestern, and LUNGevity Foundation Publish Recommendations to Simplify and Harmonize Lung Cancer Clinical TrialsAugust 30th, 2022- Will FDA Mandate More Rigorous Design for Trials of Perioperative Therapies?August 8th, 2024
